Sodium Bicarbonate Administration and Metabolic Acidosis of Preterm Infants: A Useless Therapy?

Bérengère FRANCOIS1*, Coralie LO PRESTI2, Sophie HASSID1, Renaud VIALET1 and Claire NICAISE1

1Service de réanimation pédiatrique et néonatale, Hôpital Nord, Marseille, France
2Pharmacie centrale, Hôpital Nord, AP-HM, chemin des Bourrely, France

*Corresponding author: Bérengère FRANCOIS, Service de réanimation pédiatrique et néonatale, Hôpital Nord, AP-HM, chemin des Bourrely, 13015 Marseille, France.


Received Date: 20 March, 2019; Accepted Date: 25 April, 2019; Published Date: 07 May, 2019

Abstract

Background: Metabolic acidosis due to renal loss is a common complication of prematurity. Sodium bicarbonate is still frequently used in this indication despite the lack of recommendation. The objective was to evaluate the restriction of the indication of sodium bicarbonate therapy in metabolic acidosis due to renal immaturity in preterm infants in two historical series of patients. In addition, we measured the effect of this therapy on acid-base status.

Methods: This was a retrospective monocentric study from two historical cohorts. All preterm infants under 28 weeks of gestation with metabolic acidosis (pH <7.20 and excess base (EB) ≤ -10 mmol / L) were included. During the first period (June 2011 to May 2012) patients were treated with sodium bicarbonate if the EB was ≤ -10 mmol / L. In the second period (October 2012 to September 2013), patients were treated if EB ≤ -13 mmol / L.

Results: Twenty-seven patients were included during the first period with an average gestational age of 26.5 weeks versus 38 patients during the second period with an average gestational age of 26.1 weeks (p = 0.41). In period 1, 27/27 patients (100%) were treated against 21/38 (55.2%) during the second period (p <0.001). There was no significant difference over the two periods regarding the difference in pH, pCO2 and EB between the end and the beginning of sodium bicarbonate treatment.

Conclusions: Changing our protocol decreased sodium bicarbonate use and was not associated with any change in pH, pCO2 and EB.

Keywords: Metabolic acidosis; Preterm infants; Sodium bicarbonate

Introduction

Metabolic acidosis with loss of bases is a common complication of prematurity. It is mainly due to renal immaturity [1]. Full performance of renal functions depends on gestational age and postnatal age, so that glomerular and tubular functions are immature [2,3]. Tubulopathy of preterm is responsible for excessive loss of bicarbonate due to a lack of tubular reabsorption of bicarbonate, electrolytes and small proteins that lead to metabolic acidosis, fluid, electrolyte disturbances, and weight problems [2,4,5]. Metabolic acidosis may have serious consequences: impaired cardiovascular function, cardiac arrhythmia, inflammation and decreased immune response [6]. Metabolic acidosis in prematurity has been associated with the development of intraventricular hemorrhage, periventricular leukomalacia and delayed psychomotor development [1]. For more than 60 years, sodium bicarbonate administration has been used in case of metabolic acidosis management in order to normalize the pH by acid-base reaction [7-10]. There are no recommendations in the treatment of metabolic acidosis of premature renal failure, although
this treatment is widely used. Several authors, however, have described occasional severe complications such as intraventricular hemorrhage (IVH) following the use of bolus bicarbonate infusion in preterm newborns [1,11].

The main objective of our study was to evaluate the restriction of the indication of sodium bicarbonate in metabolic acidosis due to renal immaturity in preterm under 28 weeks of gestation during two periods and to assess the outcome of untreated patients during the second period.

The secondary objective was to evaluate the consequences of this change of practice on acid-base status.

**Materials and Methods**

**Patients and methods:** This is a retrospective monocentric study in the neonatal intensive care unit of the Hôpital Nord of Marseille (France) from two historical cohorts. All preterm infants under 28 weeks of gestation with metabolic acidosis were included. Metabolic acidosis was defined as pH less than 7.20 and EB less than or equal to -10 mmol / L. During the first period, from June 2011 to May 2012, patients were treated with continuous sodium bicarbonate infusion at 1 to 2 mEq / kg / day if the EB was less than or equal to -10 mmol / L, until correction of metabolic acidosis. During the second period, from October 2012 to September 2013, patients were treated if the EB was less than or equal to -13 mmol / L. The factors taken into account were: gestational age, birth weight, age at the time of treatment, pH, pCO2 and EB (before, during and at the end of sodium bicarbonate treatment), duration of treatment, the total dose administered, the occurrence of intraventricular hemorrhage stage III and / or IV according to the classification of Papile [12].

Primary outcome was the evolution of pH, pCO2 (mmHg) and EB (mmol/l). Secondary outcome were the occurrence of IVH III and IV and duration of treatment. The first day (D 0) considered is the first day of treatment ie when the EB was less than or equal to - 10 mmol / L in the “first period” group and less than or equal to -13 mmol / L in the “second period” group. End day was the last day of treatment. For untreated patients, the D0 was when the patient had an EB less than or equal to -10 mmol / L and the end day was 3 days later.

**Statistical analysis:** The differences between the end of treatment and the day 0 were calculated, mismatched differences between the values were observed between the end and the beginning of treatment for pH, PCO2 and EB. For untreated patients in the «second period», the difference between first and third day was calculated. The comparisons between the quantitative variables were made by Student’s t-test, and by the χ2 test with a risk α fixed at 5%. The software used was PASW Statistics (V 17.0.2). The number of patients required was 32 patients (16 per group) as calculated with BioStat TGV (http://marne.u707.jussieu.fr/biostatgv/), with risk alpha 0.05 and beta 80%.

**Ethics:** The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and regional) and with the Helsinki Declaration of 1964, as revised in 2013.

**Results**

Twenty-seven patients were included during the first period with an average gestational age of 26.5 (SD 2.5) weeks versus 38 patients during the second period with an average gestational age of 26.1 (SD 1.1) weeks (p = 0.41). The mean birth weight was 0.96 kg (standard deviation: 0.45) in the first period versus 0.90 kg (standard deviation: 0.17) in the second period (p = 0.57). The main results are summarized in (Table 1).

<table>
<thead>
<tr>
<th></th>
<th>Period 1 (treatment threshold for EB&lt;sub&gt;$\leq -10$&lt;/sub&gt; mmol/L)</th>
<th>Period 2 (treatment threshold for EB&lt;sub&gt;$\leq -13$&lt;/sub&gt; mmol/L)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>27</td>
<td>38</td>
<td>p &lt; 0.001</td>
</tr>
<tr>
<td>Number of treated patients (n (%) )</td>
<td>27 (100%)</td>
<td>21 (55.2%)</td>
<td>p &lt; 0.001</td>
</tr>
<tr>
<td>Age at D0 of treatment(SD **) days</td>
<td>5.17 (1.5)</td>
<td>8.41 (4.07)</td>
<td>p &lt; 0.001</td>
</tr>
<tr>
<td>Duration of treatment H(SD **)</td>
<td>119 (72)</td>
<td>89 (57)</td>
<td>p=0.90</td>
</tr>
<tr>
<td>Duration of metabolic acidosis</td>
<td>2.04 (1.19)</td>
<td>2.87 (1.63)</td>
<td>p = 0.027</td>
</tr>
<tr>
<td>Cumulated dose grams (SD **)</td>
<td>0.6 (0.4)</td>
<td>0.3 (0.3)</td>
<td>p=0.004</td>
</tr>
<tr>
<td>pH D0 (SD **)</td>
<td>7.19 (0.1)</td>
<td>7.14 (0.1)</td>
<td>NS</td>
</tr>
</tbody>
</table>
### Table 1: Results of all patients

<table>
<thead>
<tr>
<th></th>
<th>Period 1 (treatment threshold for EB $\leq$ -10 mmol/L)</th>
<th>Period 2 (treatment threshold for EB $\leq$ -13 mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>16</td>
<td>17</td>
</tr>
<tr>
<td>Patients treated (n (%)</td>
<td>16 (100%)</td>
<td>0%</td>
</tr>
<tr>
<td>pH End$^a$ – pH D0$^*$</td>
<td>-0.02 (0.13)</td>
<td>-0.04 (0.12)</td>
</tr>
<tr>
<td>pCO$_2$ End$^a$ – pCO$_2$ D0$^*$ (mmHg)</td>
<td>12 (15)</td>
<td>8 (16)</td>
</tr>
<tr>
<td>EB$^b$ End$^a$ – EB$^b$ D0$^*$</td>
<td>2.7 (3.35)</td>
<td>0.5 (4.3)</td>
</tr>
</tbody>
</table>

Mean and standard deviation

$^a$D0 : 1st day when EB $\leq$ -10 mmol/L, $^b$End : end of treatment or at 3 days of evolution, $^c$EB : excess base, $^d$H : hours, $^e$n = number.

### Table 2: Patients with EB between –10 et -13 mmol/L

<table>
<thead>
<tr>
<th></th>
<th>Period 1 (treatment threshold for EB $\leq$ -10 mmol/L)</th>
<th>Period 2 (treatment threshold for EB $\leq$ -13 mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>16</td>
<td>17</td>
</tr>
<tr>
<td>Patients treated (n (%)</td>
<td>16 (100%)</td>
<td>0%</td>
</tr>
<tr>
<td>pH End$^a$ – pH D0$^*$</td>
<td>-0.02 (0.13)</td>
<td>-0.04 (0.12)</td>
</tr>
<tr>
<td>pCO$_2$ End$^a$ – pCO$_2$ D0$^*$ (mmHg)</td>
<td>12 (15)</td>
<td>8 (16)</td>
</tr>
<tr>
<td>EB$^b$ End$^a$ – EB$^b$ D0$^*$</td>
<td>2.7 (3.35)</td>
<td>0.5 (4.3)</td>
</tr>
</tbody>
</table>

Mean and standard deviation

$^a$D0 = 1st day when EB $\leq$ -10 mmol/L, $^b$End = end of treatment or at 3 days of evolution, $^c$EB : excess base, $^d$n = number.

### Discussion

Sodium bicarbonate treatment is very commonly used to treat metabolic acidosis in preterm infants, although there are no recommendations. Limited data had been published about this subject. The Cochrane review of 2010 found only two randomized controlled trials and one unpublished pilot study that were eligible for their criteria [1]. In our study, the protocol change did not show a significant difference on acid-base status between the treated and untreated group for an EB between -10 and -13 mmol/L. We did not find a beneficial effect of sodium bicarbonate treatment on the evolution of pH, pCO2 and EB. Untreated patients did not present more complication or deeper acidosis. Several authors have demonstrated that treatment with sodium bicarbonate in the metabolic acidosis of preterm has no effect on mortality and that it does not improve either the pH nor the psychomotor development [1,11,13-15]. Radde et al and Schwartz et al found no improvement in weight gain in these patients [16,17]. In addition, the renal immaturity responsible for this acidosis gradually corrects with age [2]. Saint-Faust et al estimated that nephrogenesis is complete between 34 and 36 GA [4]. Furthermore, treatment with sodium bicarbonate has been associated with intraventricular hemorrhage when delivered as a bolus [1,11,18]. The link between sodium bicarbonate infusion and intraventricular hemorrhage has not been established [10,15,19]. In our study we found no significant difference in the occurrence of intraventricular hemorrhage.
between the two groups. However, this study was not designed to test this specific issue and is of insufficient power to exclude this side effect. Several authors have shown that rapid sodium bicarbonate infusion modifies the cerebral perfusion rate with a risk of cerebral complications, that the effect depends on the speed of injection and that there is a dose-dependent effect [1,10,18,20]. Van-Alfen et al advocate slow infusion of sodium bicarbonate to minimize alteration of brain flow [20]. This treatment has even been associated with an increase in mortality [11]. Lawn et al, emphasize that any addition of intravenous treatment in the preterm must be carefully considered [1]. Sodium bicarbonate therapy has known side effects. It may be responsible for hypernatremia, hypercapnia, hypokalemia, hypocalcemia, hyper-osmolarity, hemodynamic changes, and QT elongation [1,14,18,20,21]. Infusion of sodium bicarbonate precipitates with many compounds and often must be administered alone which may require additional peripheral venous route for the duration of treatment and can be responsible for local complication.

The limitations of our study were a limited number of patients and a study done at two periods with the risk of change of practice causing bias, we did not evaluated the consequence on growth.

No beneficial effects of bicarbonate therapy have been demonstrated so far but there is evidence of possible adverse effects. Changing our protocol decreased sodium bicarbonate use and was not associated with any change in acid-base status. Our data did not demonstrate any benefit from bicarbonate infusion in preterm infants.

References